pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['keynote,671', 'thoracic', 'lcsm,(-blcsm)', 'keynote-671']
one of the highlights of this year thoracic track, keynote-671 by . efs hr of 0.58 (95%ci 0.46-0.72). immature but better os trends. concurrent publication in #asco23 #lcsm 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC